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ABSTRACT 
 
 The hypothesis of this project is that a functionally relevant association exists 
between CFTR and Hsp90.  In testing this hypothesis, (a) the association of CFTR and 
Hsp90 is confirmed via crosslinking and immunoprecipitation of CFTR from stably 
transfected HEK-293 cells, electrophoretic separation of cross-linked proteins, and 
protein identification via SDS-PAGE, western blotting, and mass spectrometry.    Also, 
this hypothesis is tested by (b) functionally assessing the effect of Hsp90 on CFTR 
function via Ussing chamber analysis, two-electrode voltage clamp analysis, preliminary 
in vivo animal studies, and protein phosphorylation.  The HEK-293 Flag-CFTR cells used 
in this study allows for a high degree of protein purification in quantities sufficient for 
mass spectroscopy, which has not been possible in other cell lines.   An approximately 
170 kDa band could be detected with CFTR specific antibodies.  The HEK-293 Flag-
CFTR cells also show increased protein expression levels above that observed in BHK 
cells transfected with wild-type (WT)-CFTR and CFTRhis10.  The Flag-CFTR 
expression was not only confirmed via immunofluorescent detection, but was also shown 
to be functional using a standard iodide efflux assay.  The HEK-293 Flag-CFTR cells 
responded to agonists known to activate CFTR (forskolin, IBMX, cpt.cAMP, 
isoproterenol, and adenosine).   Furthermore, these cells express sufficient quantities of 
protein to allow for mass spectrometric analysis, which has proven difficult in other cell 
lines.  Thus, this cell line is a valuable tool for the biochemical and functional 
characterization of CFTR and should prove useful for future studies assessing protein-
protein interactions as they relate to CFTR.   Using cross-linking reagents (DSP & 
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DPDPB), Hsp-90 is shown to be in association with CFTR in stably transfected HEK-293 
cells.  Hsp90 associates with CFTR under these conditions more prominently than does 
Hsp70.  The amount of Hsp90 in the macromolecular complex with CFTR is sufficient 
for mass spectrometry identification.  An in vitro assay for CFTR transport function 
(Ussing Chamber) shows that inhibition of Hsp90 with RD, an Hsp90 inhibitor with 
nanomolar affinity, decreases CFTR mediated Cl- transport.  Preliminary in vivo airway 
fluid clearance studies in mice also show that RD inhibits fluid transport, known to 
require CFTR.  Also, Hsp90 protein increases the two-electrode voltage clamp current 
measured from Xenopus oocytes expressing CFTR chloride channels.  When assessing 
the phosphorylation status of CFTR, it is seen that under conditions that increase the 
association of Hsp90, there is also observed an increase in the phosphorylation of CFTR.  
Conversely, in the presence of increasing concentrations of RD, both the Hsp90 
association CFTR and the phosphorylation of CFTR tend to decrease.  Taken together 
these data suggest that Hsp90 can be positively identified in complex with CFTR and can 
functionally regulate its activity.   
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CHAPTER 1:  GENERAL INTRODUCTION 
 
Cystic Fibrosis  
 Cystic fibrosis (CF) is the most common genetic disease affecting Caucasians.  
The disease affects approximately 1 in 2,000 to 3,000 live births (Boat, Welsh et al. 
2001).   Anderson published the first comprehensive description of CF in 1938, wherein 
the term “cystic fibrosis of the pancreas” was coined (Anderson 1938).  Soon thereafter 
in 1945, it was suggested by Farber that CF is an exocrine gland disease predominately 
characterized by an inability to clear mucus secretions.  He introduced the term 
mucoviscidosis, by which the disease is also known (Farber 1945).  In 1949, Lowe et al. 
proposed, based on an autosomal recessive pattern of inheritance, that CF must be caused 
by a defect in a single gene (Lowe, May et al. 1949; Rowe, Miller et al. 2005).  
Clinically, it was observed that the organs affected by CF such as sweat glands, airways, 
pancreas, salivary glands, epididymis, and intestine were all epithelial tissue containing 
organs.  Also, it was noted that the glands of these organs were obstructed by abnormally 
thick and dehydrated secretions (Boat, Welsh et al. 2001).  
 In the lung, mucous obstruction and infection are the major pathologic events.  It 
is likely that mucus obstruction is primary pathophysiological event.  Failure to clear 
secretions most likely provides an environment that is conducive to the establishment of 
chronic infection, leading to destruction of the respiratory tract (Boat, Welsh et al. 2001).  
The average age of death in CF patients, which is caused by respiratory insufficiency, is 
approximately 37 years of age (Davis 2006).  CF patients may predominantly have 
symptoms related to the gastrointestional tract.  Newborns with CF have meconium ileus 
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in 10%-20% of the cases.  This has been ascribed to inadequate pancreatic enzyme 
secretion.  However, it has also been suggested that the causal event may be dehydration 
of the contents of the intestine due to defective epithelial transport.  With proper 
treatment, GI abnormalities are rarely life-threatening (Boat, Welsh et al. 2001). 
 The great majority of patients with CF have exocrine pancreatic insufficiency 
from birth.  Occasionally in childhood, loss of pancreatic function is observed followed 
by pancreatitis.  In almost all cases the pancreas is abnormal and, upon autopsy, is 
observed to be virtually destroyed (di Sant' Agnese and Hubbard 1984; Atlas, Orenstein 
et al. 1992; Boat, Welsh et al. 2001).  In male patients with CF, more than 95 percent 
have altered Wolffian duct structures. Fibrosis, atrophy, or complete absence of the vas 
deferens, epididymis and seminal vesicles is observed (Taussig, Lobeck et al. 1972; Boat, 
Welsh et al. 2001). 
 In the early 1980’s, two groups published work establishing that the hallmark of 
CF epithelia is defective chloride (Cl-) transport.  First, in 1981, abnormalities in chloride 
and sodium transport in CF epithelia was described by Knowles and colleagues 
(Knowles, Gatzy et al. 1981).  Then, in 1983, chloride impermeability of the CF sweat 
ducts was demonstrated by Quinton and Bijman (Quinton and Bijman 1983). 
 Elevated sweat chloride concentrations are the most consistent functional 
alteration in CF patients.  This is not due to an increase in the number of sweat glands 
(Boat, Welsh et al. 2001).  Quinton demonstrated that the sweat gland pathophysiology is 
due to failure of the gland to reabsorb chloride along the duct (Quinton 1986).  
Interestingly, European folklore makes reference to an association between salty skin of 
infants and an early mortality (Taussig 1984).  Current diagnosis of CF is still based in 
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part upon sweat chloride levels combined with clinical criteria.  The clinical features used 
for diagnosis are typical pulmonary manifestation, typical gastrointestinal manifestations, 
and genetics (i.e., a history of CF in the immediate family).  Any one of these features 
combined with a sweat chloride level >60 meq/liter (normal = 10-35meq/liter) or with 
pathologic mutations on both chromosomes is sufficient to make a diagnosis for CF 
(Boat, Welsh et al. 2001). 
 
 CFTR Gene 
 The defective gene responsible for CF was identified by Collins, Rirodan, Tsui, 
and colleagues (Kerem, Rommens et al. 1989; Riordan, Rommens et al. 1989; Rommens, 
Iannuzzi et al. 1989).  Based upon the sequence of the CFTR gene, it was correctly 
predicted to be a member of the ATP Binding Cassette (ABC) Transporter super family 
of proteins (Figure 1-1).  Like other ABC transporters, CFTR has 2 Nucleotide binding 
domains (NBDs), and 12 membrane-spanning alpha helixes.  ABC transporters include 
genes that are known to transport organic solutes such as multidrug resistance (MDRs, or 
P-glycoprotein) genes, and a number of small nutrient and molecular transporters in both 
prokaryotic and eukaryotic systems (Borst and Elferink 2002).  The CFTR product 
encodes for a chloride channel.  When it was determined to be an ABC transporter with 
several consensus sites for protein kinase A (PKA) phosphorylation, it was suggested that 
the gene product may serve to transport out of the cell a cytoplasmic inhibitor of another 
chloride channel responsible for CF.  Thus, the name Cystic Fibrosis transmembrane 
Conductance Regulator (CFTR) was given (Riordan, Rommens et al. 1989; (Riordan, 
Rommens et al. 1989; Gadsby, Vergani et al. 2006).  However, CFTR was soon  
 3 
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Figure 1-1.  The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
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determined to hold a unique place among the ABC transporter.  Studies have confirmed 
that it does in fact serve as a chloride ion channel.  CFTR is activated directly by PKA 
phosphorylation.  The channel allows chloride ions to flow equally well in either 
direction at a conduce rate of ≤10 pS (Bear, Li et al. 1992). 
 
 CFTR Cell Biology 
 CFTR protein expression in bronchial tissue from non-CF individuals is 
primarily found in submucosal glands (specifically, the serous component of the 
secretory tubules and a subpopulation of duct cells) (Engelhardt, Yankaskas et al. 1992). 
CFTR is an apical membrane protein (Denning, Ostedgaard et al. 1992).  CFTR is present 
in the apical membrane of proximal (centroacinar and intralobar) duct epithelial cells 
with no conclusive staining in acinar cells (Marino, Matovcik et al. 1991).  CFTR is also 
present in the distal and alveolar airway epithelia (Engelhardt, Zepeda et al. 1994).  It 
functions in the transport of salt and water and is regulated by cAMP (Quinton and 
Bijman 1983; Anderson, Gregory et al. 1991; Bear, Li et al. 1992).  CFTR has also been 
demonstrated to regulate the activity of other channels and transporters including the 
epithelial sodium (Na+) channel (ENaC) (Knowles, Stutts et al. 1983; Boucher, Stutts et 
al. 1986; Stutts, Canessa et al. 1995), renal epithelial cell potassium channels ROMK1 
and ROMK2 (McNicholas, Guggino et al. 1996; McNicholas, Nason et al. 1997; Cahill, 
Nason et al. 2000), aquaporin water channel (Schreiber, Nitschke et al. 1999), and 
Cl−/HCO3− exchangers (Lee, Wigley et al. 1999; Lohi, Lamprecht et al. 2003). 
 At the time of writing, over 1500 mutations have been identified.  These 
mutations are divided into 5 general classes (Zielenski and Tsui 1995).  The ΔF508-
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CFTR mutation, which corresponds to a deletion of three base pairs, results in a loss of 
the amino acid phenylalanine at position 508 of the amino acid sequence.  The ΔF508-
CFTR  mutation accounts for approximately 70 percent of the mutations in patients with 
cystic fibrosis  (Kerem, Rommens et al. 1989).  Amino acid position 508 lies in the 
nucleotide binding domain 1 (NBD-1) of CFTR (Thomas, Shenbagamurthi et al. 1992).  
ΔF508-CFTR  mutation results in only core glycosylation of CFTR, due to the protein 
being trapped in intracellular compartments as a result of defective intracellular 
trafficking (Cheng, Gregory et al. 1990; Denning, Anderson et al. 1992; Du, Sharma et al. 
2005).  The processing defect of ΔF508-CFTR cells can be corrected in vitro.  When the 
temperature is reduced to 28-30 oC, cAMP-regulated Cl- channels appear in the plasma 
membrane and Cl- transport is restored (Denning, Anderson et al. 1992).  ΔF508-CFTR 
that happens to be present in the plasma membrane has a reduced half-life when 
compared to wild-type CFTR (Lukacs, Chang et al. 1993). It has been shown that 
ubiquitination of CFTR leads to rapid degradation (Ward, Omura et al. 1995). 
 
CFTR Physiology 
 
Alveolar Fluid Clearance 
 The general model for airway fluid clearance is that transepithelial fluid 
movement is driven by active salt transport which in turn drives osmotic water movement 
(Matthay, Folkesson et al. 2002; Matthay, Robriquet et al. 2005).  The alveolar 
epithelium comprises 99% of the lung surface area.  The barrier created by the alveolar 
epithelium and the capillaries under normal conditions has a low solute permeability.  
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The alveolar epithelium provides most of the resistance to plasma proteins due to the 
higher reflection coefficient for proteins (i.e., decreased permeability) compared to the 
capillary epithelium.  Yet, it is the primary site for the removal of excess alveolar fluid.  
The major driving force for water reabsorption is the osmotic gradient created by active 
Na+ ion transport with a confirmed role for the transport of Cl- ions as well.   
The monolayer of alveolar epithelial cells consists of  a thin layer of squamous type I 
cells (AT1) and cuboidal type II cells (AT2) (Mutlu and Sznajder 2005).   
 
Alveolar Epithelial Type II Cells 
 Because type II cells can be readily isolated and studied in vitro, they have been 
more extensively studied compared to type I cells.  The cuboidal type II cells have a 
diameter of approximately 10 μM and are the site responsible for the secretion of 
surfactant.  Also, a major driving force for the removal of fluid from the alveolar space is 
provided by active sodium and chloride transport from type II cells.  Sodium enters the 
cells through apical sodium channels (amiloride-sensitive and amiloride-insensitive) and 
CFTR may represent a rate-limiting step for salt transport by these cells (see below for 
discussion).  The sodium that enters the cells apically is extruded from the cells via the 
basolateral Na+/K +-ATPase.  This mechanism allows alveolar lung fluid to be cleared 
from the airspace and returned to the lung Interstitium and pulmonary circulation 
(Matthay, Robriquet et al. 2005; Mutlu and Sznajder 2005; Guidot, Folkesson et al. 
2006). 
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Alveolar Epithelial Type I Cells 
 The squamous type I cells have a diameter ranging from 50 to 100 μM.  They 
make up 90% of the alveolar surface (Mutlu and Sznajder 2005).  It was previously 
thought that AT2 cells are responsible for most of the vectorial apical to basolateral Na+ 
transport across the alveoli.  But, an important role has emerged for AT1 cells in vectorial 
Na+ transport.  Like the Na+/K +-ATPase, all three subunits of the epithelial Na+ channel 
(ENaC) has been demonstrated in AT1 cells, which contribute approximately 60% to 
active sodium transport.  Also, of all the mammalian cells, freshly isolated AT1 cells 
have the greatest osmotic water permeability.  This is possibly contributed by aquaporin-
5 (AQP-5) (see Figure 1-2) (Matthay, Robriquet et al. 2005; Mutlu and Sznajder 2005).    
 
Pulmonary Edema (PE) 
 Pulmonary edema (PE) is caused by an increased accumulation of fluid in the 
lung airspace and impaired function of the active Na+ and Cl- transport mechanisms that 
normally serve to remove fluid from the alveoli (Factor, Mutlu et al. 2007). The two 
fundamentally different types of pulmonary edema that occur in humans are known as 
cardiogenic pulmonary edema and noncardiac pulmonary edema (Figure 1-2). Cardiac 
pulmonary edema is also known as hydrostatic or hemodynamic edema.  Non-cardiac 
pulmonary edema is also known as increased-permeability pulmonary edema, acute lung 
injury, or acute respiratory distress syndrome.  Cardiogenic and noncardiogenic 
pulmonary edema have distinct cause, yet they present similar clinical manifestations that 
make them difficult to distinguish (Ware and Matthay 2005). 
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Figure 1-2.  Pulmonary Edema 
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 Fluid and protein leakage into the airspace of normal lungs occurs primarily 
through small gaps that exist between endothelial cells and capillaries.  Due to the tight 
junctions, fluid and solutes from the circulation usually will not enter the alveoli.  Fluid 
will typically move proximal to the alveolar space into the peribronchovascuar space. 
The lymphatics will then return the fluid from the interstitium to the circulation.  The 
forces affecting fluid filtration across the lung microcirculation are derived from a 
combination of hydrostatic forces and protein osmotic forces.  The hydrostatic force is 
approximately equal to the hydrostatic pressure in the pulmonary capillaries.  This is only 
partially offset by a protein osmotic pressure gradient due to the restricted movement of 
larger plasma proteins (Ware and Matthay 2005). 
 Cardiogenic or volume overload edema is characterized by a rapid increase in 
hydrostatic pressure.  This leads to an increase in fluid filtration from the 
microcirculation.  An increase in pulmonary venous pressure from an increase in left 
ventricular end-diastolic pressure and left atrial pressure usually causes the increased 
hydrostatic pressure.  With elevations of 18 to 25 mm Hg, edema will begin in the 
perimicrovascular and peribronchovascuar interstitial spaces.  Beyond 25 mm Hg, fluid 
that has a low protein concentration will begin to be seen in the alveolar spaces (Staub 
1974; Ware and Matthay 2005).  
 Noncardiac pulmonary edema is characterized by an increase of fluid with a 
high plasma protein concentration into the interstitium and alveoli due to an increase in 
vascular permeability.  The amount of fluid that accumulates in the alveolar space 
depends upon the degree of interstitial edema, whether or not the alveolar epithelium has 
been injured, and the ability of the alveolar epithelium to actively transport the alveolar 
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fluid.  There is usually a decreased capacity to resolve the alveolar edema fluid when the 
alveolar epithelial damage is due acute lung injury (Matthay, Folkesson et al. 2002; Ware 
and Matthay 2005). 
 
Acute Lung Injury (ALI) 
 First described in 1967, acute lung injury (ALI) and acute respiratory distress 
syndrome (ARDS) are characterized by “the abrupt onset of clinically significant 
hypoxemia with presence of diffuse pulmonary infiltrates” (Wheeler and Bernard 2007).  
Due to an increase in vascular permeability, the infiltrates appear on radiographs as 
pulmonary edema.  The number of cases that occur every year are in the hundreds of 
thousands (Goss, Brower et al. 2003).  Within 7-10 days, about half of the patients with 
ALI will have died.  Within the 50% that survive, a majority of them will have a 
prolonged recovery.  Up 10% of those with ALI will be on ventilation for more than a 
month.  The lung function of ALI survivors will not return for more than 6-12 months 
(Ashbaugh, Bigelow et al. 1967; Wheeler and Bernard 2007). 
 The disorder can be caused by indirect or direct injury.  Examples of direct 
injury include: alveolar hemorrhage, drowning, fat and amniotic-fluid embolism, gastric 
aspiration, pneumonia, pulmonary contusion, reperfusion (pleural effusion drainage, 
embolectomy), smoke and toxic gas inhalation, and unilateral lung re-implantation.  
Examples of indirect injury include:  pancreatitis, severe sepsis, shock, salicylate or 
narcotic overdose, blood transfusion  (Wheeler and Bernard 2007).  
  ALI manifests as ARDS when the acute lung injury is severe.  ARDS has a 
mortality rate of 30-50%.  ARDS is characterized by the infusion of the alveolar air 
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spaces with fluid containing a high plasma protein concentration typical of 
noncardiogenic pulmonary edema.  ARDS can develop in response to inflammatory 
stress from both indirect and direct causes of acute lung injury including sepsis, trauma, 
and severe pneumonia (Matthay, Folkesson et al. 2002; Ware and Matthay 2005; Guidot, 
Folkesson et al. 2006).   
 Early acute lung injury is characterized by an initiation and perpetuation of 
inflammation by various cytokines such as tumor necrosis factor, interleukin 1, and 
interleukin 8.  As a result of increased oxidant stress and protease activity, widespread 
lung collapse (atelectasis) occurs due to decreased surfactant production and inactivation 
of residual surfactant.  Also, elastases present in the lung cause structural damage to the 
lung leading to injury of both the epithelial cells and the alveolar-capillary network.  
Alveolar fluid accumulation is thereby increased due to the damage incurred by the 
epithelial cell barrier.  The epithelial cell layer damage also delays patient recovery by 
slowing resolution of the pulmonary edema (Sartori and Matthay 2002; Wheeler and 
Bernard 2007). 
 
Pulmonary Edema, Acute Lung Injury, and Alveolar Fluid Clearance 
 Pulmonary edema is a condition that is life threatening.  Pulmonary edema 
develops either due to an increase in permeability of the lung alveolar-epithelial barrier or 
from an increase in lung vascular hydrostatic pressure.  Often it will develop into acute 
respiratory failure, which is commonly caused by ALI and ARDS.  Much has been 
learned about the pathophysiology of ALI/ARDS.  They are well defined pathologies and 
readily recognized clinical disorders.  They can be caused by clinical insults to the lung 
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or by predispositions to lung injury.  Increased pulmonary edema, alveolar flooding, and 
respiratory failure are characterized by alveolar epithelial and lung endothelial injury in 
the early stages of ALI/ARDS.  In order for ALI/ARDS to be resolved, it is necessary 
that the alveolar space have its pulmonary edema fluid reabsorbed (airway fluid 
clearance).  Resolution of experimentally induced pulmonary edema and acute lung 
injury requires intact alveolar epithelial fluid transport (Ware and Matthay 2001; Wheeler 
and Bernard 2007).    
 Active transport of salt and water from the lung across the epithelial barrier is 
required for airway fluid clearance to take place.  Airway fluid clearance requires apical 
ion transporters for sodium (epithelial sodium channels) and chloride (cystic fibrosis 
transmembrane conductance regulator – CFTR).  Also, the Na+/K+-ATPase in epithelial 
cells plays a centrally important role in airway fluid clearance.  If the alveolar epithelium 
is injured and the barrier disrupted, ion channels can be down-regulated which will 
further reduce net airway fluid clearance.  This process results in enhanced alveolar 
edema.  The rate of airway fluid clearance is controlled by catecholamine-dependent, as 
well as catecholamine-independent mechanisms (Matthay, Folkesson et al. 2002; Guidot, 
Folkesson et al. 2006).  Understanding the processes that upregulate epithelial sodium 
and chloride transport, enhancing airway fluid clearance, can potentially lead to more 
effective treatments for some types of airway lung injury and pulmonary edema (Sartori 
and Matthay 2002; Mutlu, Koch et al. 2004; Mutlu and Sznajder 2005).  (Figure 1-3). 
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Figure 1-3.  Airway Fluid Clearance 
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CFTR, the Epithelial Sodium Channel (ENaC), and the Beta -2 Adrenergic 
Receptor (β2-AR) in Alveolar Fluid Clearance 
 While most agree that active sodium transport has a primary role in 
transepithelial movement of salt and water in alveolar epithelial of lung, an important role 
for CFTR mediated upregulation of airway fluid clearance is being established (Matthay, 
Robriquet et al. 2005).  The basic model for vectorial ion transport (sodium and chloride) 
is that salt movement creates a slight osmotic gradient in the interstitial space outside the 
alveoli that removes water from the distal air spaces of the lung (airway fluid clearance).  
CFTR and epithelial sodium channels (ENaC) are expressed in distal and alveolar airway 
epithelia (Engelhardt, Zepeda et al. 1994).  A study in alveolar type II cells suggests that 
cAMP driven sodium uptake may depend initially on the uptake of chloride (Jiang, 
Ingbar et al. 1998).  It has been shown that alveolar type II cells express CFTR protein 
and CFTR can be detected via patch-clamp analysis, short-circuit studies, as well as in 
vitro vectorial fluid transport assays.  In vivo evidence also indicates that, in the intact 
lung, CFTR plays an important role in cyclic adenosine monophosphate (cAMP) 
activated airway fluid clearance (Matthay, Robriquet et al. 2005; Guidot, Folkesson et al. 
2006).   
   Beta (β)–Adrenergic receptors (β2-AR) are present in the alveolar epithelium 
where they upregulate the active Na+ transport and thereby accelerate airway fluid 
clearance form the alveolar airspace (Mutlu, Adir et al. 2005).  Β2-AR signaling increases  
transepithelial Cl- movement across airway and alveolar epithelial cells through CFTR 
(Engelhardt, Zepeda et al. 1994; Jiang, Ingbar et al. 1998).  Not only does activation 
ofΒ2-AR upregulate CFTR-dependent chloride transport, but it also upregulates ENaC-
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dependent sodium transport (Guidot, Folkesson et al. 2006).  A study of alveolar type II 
cells kept at an apical air-liquid interface shows that β-adrenergic agonists cause 
activation of apical chloride channels and enhanced sodium absorption (Jiang, Ingbar et 
al. 2001) (Figure 1-4). 
 Further studies in the mouse and human came to the same conclusion.  Using a 
pharmacological approach, namely glibenclamide, it was suggested that cAMP-
stimulated airway fluid clearance from the distal airspaces of the lung may require 
chloride uptake and CFTR-like transport (Factor, Mutlu et al. 2007).  It is true that the 
inhibitory effect of glibenclamide inhibitory is not specific for CFTR, as it can also 
inhibit potassium channels.  However, these results are confirmed when CFTRinh-172 (a 
specific CFTR inhibitor) is used (Fang, Song et al. 2006). 
 More direct evidence has also been provided from in vivo studies using the 
ΔF508-CFTR -CFTR mouse model.  While there is evidence for enhanced sodium 
absorption in the upper airways due to the absence of CFTR (Stutts, Canessa et al. 1995), 
it is becoming clear that, in the distal air spaces, an absence of CFTR decreases the 
stimulated salt and fluid transport (Matthay, Robriquet et al. 2005).   This is similar to the 
effect of CFTR on sodium absorption in the human sweat duct (Reddy, Light et al. 1999).   
In ΔF508-CFTR mice, fluid clearance does not increase in the presence of either β-
adrenergic agonists or forskolin to the same extent as do wtCFTR mice (Mutlu, Koch et 
al. 2004).  These studies show that CFTR is essential for cAMP –mediated enhancement 
of airway fluid clearance from the distal airspaces of the lung (Fang, Fukuda et al. 2002).  
In addition, transfer of the β2-AR gene was studied in the alveolar epithelium of the  
ΔF508-CFTR mice.  Again, it was found that, compared to wild-type controls, the 
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Figure 1-4.  Role of CFTR in Airway Fluid Clearance 
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absence of functional CFTR hinders active alveolar Na+ transport.  This suggests that 
much of the β-Adrenergic upregulation of Na+ flux is regulated by  
CFTR (Mutlu, Adir et al. 2005).  Furthermore, it is important to note that while ΔF508-
CFTR -CFTR mice have normal basal airway fluid clearance rates, they are unable to 
increase active sodium transport in response to edema formation (Fang, Fukuda et al. 
2002; Mutlu, Adir et al. 2005). 
 Thus, it seems that there is a close working relationship between CFTR, ENaC, 
and the β2-AR in regulating airway fluid clearance.  Both the β2-AR and CFTR seem to 
be required to upregulate active alveolar Na+ transport.  It is of concern for patients with 
cystic fibrosis that they may be impaired in their ability to effectively initiate airway fluid 
clearance in response to airway lung injury and pulmonary edema (Mutlu, Adir et al. 
2005). 
 
CFTR Interacting Partners 
 
Protein-Protein Interaction in the Lung 
 It is common for macromolecular complexes of cells to form on membrane 
domains to increase signaling efficiency (Li and Naren 2005).  CFTR-dependent chloride 
transport is stimulated by isoproterenol (Haws, Finkbeiner et al. 1994).   In airway 
epithelial cells, the major adrenergic receptor isoform expressed is the β2-AR (Abraham, 
Kottke et al. 2003).  It has recently been established that both CFTR and the β2AR can, 
through their PDZ motif, bind NHERF1/ ERM binding phosphoprotein of 50 kDa 
(EBP50) (Naren, Cobb et al. 2003).  Also, G proteins are likely to be in the complex.  
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These proteins can associate with the β2AR and protein kinase A (PKA) that anchors to 
A-kinase–anchoring proteins (AKAP) (ezrin).  When activated by isoproterenol, the 
β2AR stimulates the Gs pathway leading to an increase in cAMP.  The local increase in 
cAMP then allows PKA to become active, phosphorylating and activating CFTR.  When 
the PDZ motif is deleted from CFTR, the interaction is both physically and functionally 
uncoupled.  This effect is specific for β2AR and is not seen with other receptors such as 
the adenosine receptor pathway (Naren, Cobb et al. 2003).  
 
Amino-Terminal SNARES 
 Syntaxin 1A and soluble NSF attachment protein of 23 kilodaltons (kDa) 
(SNAP-23) are known as target soluble NSF attachment protein receptors (t-SNARES).  
It has been shown that they are both localized to the apical membrane of epithelial cells.  
It has also been shown that the function of CFTR can be down-regulated by Syntaxin 1A 
and SNAP-23 (Naren, Nelson et al. 1997; Naren, Quick et al. 1998; Peters, Qi et al. 1999; 
Cormet-Boyaka, Di et al. 2002).  Syntaxin 1A interacts with the amino-terminal (N-
terminal) domain of CFTR (Naren, Quick et al. 1998).  This interaction is also 
physiologically significant.  CFTRs activity can be increased by 2-4 fold by perturbing 
the protein-protein with Syntaxin 1A.  Likewise, it has been demonstrated that when 
SNAP-23 binds to the N-terminus of CFTR, functional CFTR activity decreases.  These 
two proteins (Syntaxin 1A and SNAP-23) work synergistically to inhibit CFTR function, 
resulting in greater inhibition together compared to either protein alone.  (Naren, Nelson 
et al. 1997; Cormet-Boyaka, Di et al. 2002).   
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Carboxy-Terminal PDZ Motifs 
 Among the various conserved protein domains found in mammalian proteins, 
PSD95/ DlgA /zo-1 (PDZ) domains are among the most common (Shenolikar, Voltz et 
al. 2004).  PDZ domains are made up of 80–100 amino-acid sequences. Protein–protein 
interactions are mediated through these domains by binding to short peptide sequences 
that are usually found in the carboxyl (C) termini of protein binding partners.  PDZ 
domains play a role in a variety of cellular functions including:  mediating protein–
protein interactions, assisting in the polarized localization of various proteins, cellular 
colocalization (transporters, signaling proteins, and channels) regulating endocytic 
trafficking and controlling channel function and transporter function (Brone and 
Eggermont 2005).  PDZ domains are found in several ABC transporters.  CFTR, 
ABCA1, ABCA7, MRP2 and MRP4 have C terminal PDZ-binding motifs (Hegedus, 
Sessler et al. 2003).  The CFTR PDZ motif sequence is aspartic acid- threonine-arginine-
leucine (DTRL).  This motif allows CFTR to bind several PDZ domain containing 
proteins such as Na+/H+ exchanger regulatory factor isoform-1 (NHERF1), NHERF2, 
NHERF3, or CFTR-associated protein - 70 kDa (CAP70 or NHERF4) and CFTR-
associated ligand (CAL) (Wang, Raab et al. 1998; Guggino 2004; Li and Naren 2005; 
Thelin, Hodson et al. 2005).  C-terminal ezrin, radixin, or moesin (ERM)-binding domain 
is present in NHERF1 and NHERF2, allowing them to interact with ezrin, radixin, or 
moesin.  This allows proteins that bind NHERF to interact with the actin cytoskeleton in 
the apical membrane of polarized epithelial cells (Short, Trotter et al. 1998; Sun, Hug et 
al. 2000).  
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Nucleotide Binding Domains (NBDs) – Scaffolding Proteins 
 It has been proposed that the nucleotide binding domain itself may allow CFTR 
to function as an actin-binding protein.  It has been demonstrated that CFTR function can 
be regulated by the actin cytoskeleton (Prat, Xiao et al. 1995; Cantiello 1996; Prat, 
Cunningham et al. 1999).  Also, using a lipid bilayer system and atomic force microscopy 
(AFM), purified human CFTR has been shown to interact directly with CFTR (Chasan, 
Geisse et al. 2002).  And CFTR has been shown to exist as a dimer (Li, Roy et al. 2004).  
Also, it has been shown that dimerization of CFTRs nucleotide-binding domains are 
involved in the regulation of ion channel activity (Vergani, Lockless et al. 2005).  
Interestingly, a comparison of the amino acid sequences between CFTR and various actin 
binding proteins shows strong homology.  It turns out that the two nucleotide binding 
domains of CFTR have sequence homology with actin capping and cross-linking proteins 
such as filimin and alpha (α) - actinin.  Also, consensus sequences of strong homology 
exist between the nucleotide binding domains (NBDs) and the actin binding proteins 
gelsolin, severin, and villin (Prat, Xiao et al. 1995).  If the NBDs are indeed interacting 
directly with the actin cytoskeleton, this may in part explain the ability of the actin 
cytoskeleton to regulate CFTR channel activity.  
 
Hsp90 and Chloride Channel Regulation 
Hsp90 is a chaperone protein that binds to other proteins that are at a late stage of 
folding and consequently in a near native conformation (Jakob, Lilie et al. 1995; Young, 
Moarefi et al. 2001).  HSP90 is an ATP dependent chaperone (Prodromou, Roe et al. 
1997).  ATP binds Hsp90 in the highly conserved 25kDa N-terminal domain.  This is the 
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site of action for the Hsp90 inhibitor, Radicicol.  Radicicol is a natural compound that 
inhibits Hsp90 with nanomolar affinity by occupying the nucleotide binding pocket 
within the N-terminal domain (Roe, Prodromou et al. 1999).   
 Hsp90 has a demonstrated role in regulation of Cl- channel function.  CLC-2, is 
a chloride channel that has been shown to play a role in various physiological functions 
including epithelial fluid transport (Jentsch, Poet et al. 2005).  In HEK-293 cells stably 
expressing CLC-2, an association with Hsp90 has been demonstrated via 
immunoprecipitation and mass spectroscopy.  Also, Radicicol was shown to reduce 
plasma membrane channel abundance without affecting total amounts of CLC-2.  
Functional experiments using whole cell patch clamping show that inhibition of Hsp90 
reduced CLC-2 activity and association of Hsp90 with CLC-2 leads to an increase in 
channel activity (Hinzpeter, Lipecka et al. 2006).  Interestingly, while it has been shown 
that Hsp90 may be found in association with CFTR (Loo, Jensen et al. 1998), the 
functional importance of this protein-protein has not been thoroughly investigated.   
 
Hypothesis and Specific Aims 
The hypothesis of this project is that a functionally relevant association exists 
between CFTR and Hsp90.  In testing this hypothesis, (a) the association of CFTR and 
Hsp90 is confirmed via crosslinking and immunoprecipitation of CFTR from stably 
transfected HEK-293 cells, electrophoretic separation of cross-linked proteins, and 
protein identification via SDS-PAGE, western blotting, and mass spectroscopy.    Also, 
this hypothesis is tested by (b) functionally assessing the affect of Hsp90 on CFTR 
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function via using chamber analysis, two-electrode voltage clamp analysis, preliminary in 
vivo animal studies, and protein phosphorylation. 
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CHAPTER 2:  PURIFICATION OF FLAG-CFTR FROM HEK-293 CELLS 
 
Materials and Methods 
 
Generation of HEK-Flag-CFTR Cell Line 
 HEK-Flag-CFTR cell line was generated in collaboration with the John Kappes 
laboratory of The University of Alabama at Birmingham as described previously 
(Naldini, Blomer et al. 1996; Wu, Wakefield et al. 2000).  HEK-293 cells were plated on 
100-mm-diameter dishes at a density of approximately 106 cells per dish. The following 
day, cells were transfected using the three-plasmid lentiviral vector system.  To produce 
the virus, 25.0 µg of vector genome plasmid containing Flag-CFTR, 50.0 µg of a 
backbone plasmid expressing HIV-1 gag and pol genes, and 5.0 µg of a plasmid that 
expresses vesicular stomatitis virus (VSV) G protein were used to transfect each 100-mm 
dish of cells.  The transfection was performed using a Profection kit (calcium chloride) 
from Promega. On the following day, the medium was replaced, and 2 days after 
transfection, supernatant from vector-producing 293T cells was harvested, passed 
through a 0.45-μm-pore-size filter to remove producer cells, and then subjected to 
centrifugation at 4°C and 27,500 × g for 30 min to concentrate the virus.  The virus pellet 
was resuspended in 1.0 ml of DMEM.  Concentrated vector (0.8 ml) was used to infect 1 
x 106 HEK-293 cells in a 100-mm dish. After 2 days, infected cells were split into two 
100-mm dishes following a 5 minute trypsin treatment.  The infected cells were selected 
in Dulbecco’s modified Eagle’s medium (DMEM) containing puromycin [5 µg/mL].  
After 12 days of puromycin selection, a microscope was used to identify individual 
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colonies.  The HEK-Flag-CFTR cells were cultured and maintained at 37oC in DMEM 
containing 10% Serum Supreme (Lonza Group Ltd, Switzerland), 100 U of penicillin, 
and 0.1 mg/ml of streptomycin (Sigma). 
 
Protein Purification  
 HEK-Flag-CFTR cells were lysed PBS 0.2% Triton X-100 with protease 
inhibitors (aprotenin [1μg/mL], leupeptin 1 μg/mL, pepstatin 1 μg/mL, PMSF [400 μM]).  
The lysate is centrifuged at 16,000 x g for 10 min at 4oC.  Then, immunoprecipitation is 
performed on the lysate overnight at 4oC while rotating using Flag antibody conjugated 
beads (Seize Immunoprecipitation Kit, Pierce Chem. Co.).  The proteins are then bound 
to spin columns, spun for [insert] minutes at 3,000 g and washed with lysis buffer.  
Proteins were eluted from beads using 100mM Glycine pH 2.2 (0.2% Triton) into 1.5 M 
Tris (pH 8.8).  The eluted protein was then was separated on a 4-15% SDS 
polyacrylamide gel (SDS-PAGE) and visualized with Gel Code Blue (Pierce.) 
 
Purification of the Cross-Linked Macromolecular Complex 
 HEK-Flag-CFTR cells cross-linked with dithiobis(succinimidyl)propionate 
(DSP) were solubilized in 1X RIPA buffer (NaCl 140 mM, Nonidet P40 (NP40) 1%, Na-
deoxycholate 0.5%, sodium dodecyl sulfate (SDS) 0.1%, Tris-HCl 50 mM, pH 8.0) plus 
protease inhibitors on ice for 20 min, and lysates were spun at 15,000 g for 15 min at 4°C 
to pellet insoluble material. 40 µg of the clarified protein lysate (protein was estimated 
using Bio-Rad Protein Assay #500-0006).  Anti-Flag beads were incubated with the 
cross-linked supernatant overnight at 4°C with constant mixing on a rotator. After 
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washing the beads three times with RIPA buffer, the cross-linked proteins were eluted 
with sample buffer.  During this process, 2.5% ß-mercaptoethanol (βME) cleaved the 
disulfide bond of the DSP, separating the proteins. The immunoprecipitated proteins were 
separated on 4–15% gel.  For western blotting, proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane, blocked with TBST containing 5% milk, 
and blotted using α-CFTR monoclonal antibody (R1104) and α-HSP-90 monoclonal 
antibody (HSP90/F8).  
 
CFTR Physiological Assay – Iodide Efflux 
 CFTR-mediated halide conductance was measured using the iodide efflux assay 
(Chang et al., 1993).  Calu-3 and HEK-293 cells were grown to confluency on 60 mm-
dishes.  The cells were loaded with 136 millimolar (mM) sodium iodide (NaI) for 1 hour 
at 37 0C.  The dishes were washed 5 times with 1 mL of warm 136 mM sodium nitrate 
(NaNO3) at 37 0C to remove extracellular NaI from the cells.  The functional activity of 
CFTR is assessed by stimulating the cells with agonist and measuring the release of NaI 
(through CFTR channels) into the extracellular buffer (NaNO3).  For 10 minutes, the 
cells were incubated with 1 mL of warm 136 mM NaNO3.  The buffer was collected and 
replaced every minute.  The first four minutes of incubation were considered as the 
baseline period.  The fifth through tenth samples contained CFTR agonists.  The reagents 
being investigated for their effect on CFTR function were either pre-incubated prior to 
the assays initiation, were added to both the baseline and activation phases of the assay, 
or were added to the activation phase alone.  The iodide concentration in each 1 mL 
aliquot was assessed using a ThermoOrion 720 iodide sensitive electrode (Orion 
Research, Inc., Boston, MA).  The iodide was converted to nanomoles/min and expressed 
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as mean values (+/-) standard deviation (SD) using the Student's t test.  A value of 
probability (P) < 0.05 was used as a cut-off for determination of statistical significance.   
 
Mass Spectrometry 
 Identification of FLAG-CFTR was confirmed using liquid chromatography 
coupled to electrospray-ionization quadrupole ion trap mass spectrometry (LC-ESI-QIT-
MS) (Gadgil, Pabst et al. 2003).  Samples were analyzed on a ThermoFinnigan LCQ 
DECA mass spectrometer.  Picofrit columns (360 am outer diameter (OD), 75 am inner 
diameter (ID), 15μm orifice, New Objective, Woburn, MA, USA) were packed with 9-10 
cm of C18 silica based reverse-phase packing material (5 um particle diameter, 200 Å 
pore size, MAGIC C18) from Michrom BioResources Auburn, CA, USA.  Samples were 
extracted using ZipTip C18 microcolumns, eluted with 50% acetonitrile, dried, and 
redissolved in 4 μL of 0.1% Trifluoroacetic acid (TFA) in water. This purified sample 
was injected into a Surveyor LC system (Thermo Finnigan, San Jose, CA, USA).  
Chromatography of FLAG-CFTR was performed by the Picofrit column using a linear 
gradient of increasing acetonitrile [100% solution A (water with 0.1% formic acid) to 
50% solution B (90% acetonitrile, 10% water, 0.1% formic acid], at a flow rate of 400 
nanoliter (nL) / minute, which was then sprayed into the mass spectrometer.   Three types 
of spectra were acquired:  a full-scan of the mass spectrum, a zoom scan of the two most 
prominent ions, and MS/MS scans of the two most prominent ions. The spectra were 
analyzed by SEQUEST software (ThermoFinnigan) which uses an algorithm to match 
observed peptide masses and MSMS product ion masses to the theoretical values for all 
proteins in the database.  FLAG-CFTR identity was also determined using a different 
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form of mass spectrometry called MALDI-TOF (matrix assisted laser desorption 
ionization – time-of-flight). Spectra were scored using a MOWSE scoring algorithm 
(Pappin, Hojrup et al. 1993).   
 
Results 
 
Purification of CFTR (Microgram Quantities) 
Here, we describe the characterization of a novel CFTR expressing cell line, the 
FLAG-CFTR HEK-293 cells.  These cells were developed to provide a cell line that 
would allow a both a functional and biochemical characterization of wild-type CFTR.  In 
collaboration with Dr. John Kappes (University of Alabama at Birmingham), we 
developed a human embryonic kidney (HEK-293) cell line expressing wild-type CFTR.  
Using this cell line has several advantages.  First, it is of human origin, unlike the 
LLCPK1 (pig), C127 (mouse), or BHK (hamster).  Second, compared to LLCPK1 and 
MDCK cells, FLAG-CFTR HEK-293 cells are easier to transfect.   Third, the CFTR in 
these cells respond to various agonists, such as adenosine and β-adrenergic receptor 
agonists.  This is important because not all cells lines respond to this agonist profile (i.e., 
BHK cells).  And fourth, the CFTR in these cells are engineered with a FLAG-tag on the 
fourth extracellular loop (Figure 2-1).  This allows for a high degree of protein 
purification in quantities sufficient for mass spectroscopy.  It also offers the ability to 
immunoprecipitate larger quantities of proteins that interact with CFTR.  The cells were 
lysed in RIPA buffer and 40 μg of the clarified protein was analyzed by Western Blot 
using an α-CFTR monoclonal antibody (R1104).  As expected a 170 kDa band of Flag-
CFTR was detected (Figure 2-2).   
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Figure 2-1.  Flag-CFTR 
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Figure 2-2.  HEK-Flag-CFTR Cells Express Detectable CFTR 
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HEK-293-FLAG-CFTR cell lysates were compared to BHK cells transfected with 
wild-type (WT)-CFTR and CFTRHis10.  Each lane was loaded with 40 μg of protein and 
probed with CFTR mAb (R1104).  With a 10 second exposure, the HEK-293-CFTR 
transfected cells compared to clearly shows a much greater amount of protein being 
expressed (Figure 2-3).    
 Next, the amount of FLAG-CFTR expressed in these cells in these cells was 
quantified using MBP-C-CFTR as a standard.  A confluent 60-mm dish (~106 cells) 
yielded 1320 μg of protein (3.3 millligrams (mg) / milliliter (mL)).  20 μg of protein was 
loaded on a gel along with MBP-CFTR (0.5 ng-10.0 nanograms (ng)).  As determined 
from the standard curve, 0.851pmoles (125 ng) of CFTR is expressed in 20 µg of protein 
lysate.  This corresponds to 8.2 μg of total FLAG-CFTR per 106 cells (Figure 2-4).   
 
Flag-CFTR Cell Line Functional Assay 
 Cells containing CFTR respond to agonists that increase the PKA 
phosphorylation of CFTR (forskolin, 3-Isobutyl-1-methylxanthine (IBMX), and 
cpt.cAMP) (Anderson, Rich et al. 1991; Cheng, Rich et al. 1991).  It is expected that if 
the Flag-CFTR is functional in the stably transfected HEK-293 cells, it will respond to 
agonists known to activate CFTR.  Using the iodide efflux assay, the HEK-Flag-CFTR 
cells were shown to have functional CFTR activity.  As anticipated, the HEK-FLAG-
CFTR cells responded to forskolin, 3-Isobutyl-1-methylxanthine (IBMX), and cpt.cAMP 
(10 μM, 50 μM, and 100 μM respectively), isoproterenol (100 μM), and adenosine (100 
μM).  This demonstrates that the Flag-CFTR expressed within the cells is able to exhibit 
functional activity (Figure 2-5). 
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Figure 2-3.  HEK-Flag-CFTR and BHK Cell Expression of CFTR 
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Figure 2-4.  Quantitation of HEK-Flag-CFTR 
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Figure 2-5.  HEK-293-Flag-CFTR Cells Respond to CFTR Activating Agonists  
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Mass Spectrophotometric Identification of CFTR 
 It is expected that sufficient quantities of Flag-CFTR can be purified to confirm 
the protein identity via mass spectrometry.  Flag-CFTR lysate was incubated overnight 
with anti-flag antibody beads.  The lysate with then eluted and protein concentration was 
determined.  Purified CFTR protein (~6 µg/lane) was subjected to 4-15% SDS-
polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie blue (Figure     
2-6).  The band of interest was excised, trypsin digested, and extracted using ZipTip C18 
microcolumns.  Proteins were eluted with 50% acetonitrile, dried, and redissolved in 4 
µL of 0.1% Trifluoroacetic acid (TFA) in water.  Chromatography of the sample was 
performed using a linear gradient of increasing acetonitrile at a flow rate of 400 nanoliter 
(nL) / minute and sprayed into the mass spectrometer. Three types of spectra were 
acquired:  a full-scan of the mass spectrum, a zoom scan of the two most prominent ions, 
and MS/MS scans of the two most prominent ions.  Spectra were analyzed by SEQUEST 
software and scored using a MOWSE scoring algorithm.  Anything above a score of 65 is 
considered significant and a positive identification of the protein sample.  Four peaks 
were positively identified as CFTR with MOWSE scores as high as ~ 135.  Thus, the 
peptide peaks were positively identified as human CFTR (Figure 2-7). 
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Figure 2-6.  Purification of Flag-CFTR 
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Figure 2-7.  Mass Spectrometry: Identification of Flag-CFTR 
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CHAPTER 3:  HSP-90 AND CFTR:  ASSOCIATION AND FUNCTIONAL 
INTERACTION 
 
Materials and Methods 
 
Coimmunoprecipitation and Immunoblotting 
 Dithiobis(succinimidyl)propionate (DSP) [1mM] was prepared by initially 
solubilizing in 40 μL of DMSO, followed by addition of 10 mL of PBS warmed to 370C.  
HEK-Flag-CFTR cells were cross-linked with (DSP) [1mM] for 10 minutes at 370C.  
Cells were then solubilized in modified radioimmunoprecipitation (RIPA) buffer (NaCl 
140 mM, Nonidet P40 (NP40) 1%, Na-deoxycholate 0.5%, sodium dodecyl sulfate (SDS) 
0.1%, Tris-HCl 50 mM, pH 8.0) plus protease inhibitors on ice for 20 min, and lysates 
were spun at 15,000 g for 15 min at 4°C to pellet insoluble material. 40 µg of the clarified 
protein lysate (protein was estimated using the dye binding method.  Anti-Flag beads 
were incubated with the cross-linked supernatant overnight at 4°C with constant mixing 
on a rotator. After washing the beads three times with RIPA buffer, the cross-linked 
proteins were eluted with sample buffer.  During this process, the 2.5% ß-
mercaptoethanol cleaved the S-S bond of the DSP, separating the proteins. The 
immunoprecipitated proteins were separated on 4–15% gel.  For western blotting, 
proteins were transferred to a polyvinylidene difluoride (PVDF) membrane and blotted 
using α-CFTR monoclonal antibody (R1104) and α-Hsp-90 monoclonal antibody 
(Hsp90/F8).  
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Protein Purification  
 HEK-Flag-CFTR cells were lysed PBS 0.2% Triton X-100 with protease 
inhibitors (aprotenin [1μg/mL], leupeptin 1 μg/mL, pepstatin 1 μg/mL, PMSF [400 μM]).  
The lysate is centrifuged at 16,000 g for 10 min at 4oC.  Then, immunoprecipitation is 
performed on the pre-cleared lysate overnight at 4oC while rotating using Flag antibody 
conjugated beads (Seize Immunoprecipitation Kit, Pierce Chem. Co.).  The proteins are 
then bound to spin columns, spun for [insert] minutes at 3,000 g and washed with lysis 
buffer.  Immunoprecipitated material eluted from beads using 100mM Glycine pH 2.2 
(0.2% Triton) into 1.5 M Tris (pH 8.8).  The eluted protein was then was separated on a 
4-15% SDS polyacrylamide gel (SDS-PAGE) and visualized with Gel Code Blue 
(Pierce.) 
 
Short-Circuit Current Assay 
 Calu-3 cells were grown to confluency as polarized monolayers on Costar 
Transwell permeable supports with a filter area of 0.33 cm2.  Short-circuit current 
measurements were recorded after mounting filters in an Ussing chamber as previously 
described (Li, C, et al. 2004).  Epithelia were maintained at 37 oC and gassed with 95% 
O2 and 5% CO2 while being bathed in low Cl- Ringer’s solution on the apical side of the 
monolayer (mM): (133.3 Na-gluconate, 5 K-gluconate, 2.5 NaCl, 0.36 K2HPO4, 0.44 
KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 Hepes, 10 mannitol, pH 7.2, [Cl] = 14.8) 
and normal Ringer’s solution basolaterally (mM): (140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 
KH2PO4, 1.3 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 Hepes, 10 glucose, pH 7.2, [Cl–] = 
149).  Radicicol [1 mM] was added to the apical and serosal sides of the cell monolayers 
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for 30 minutes prior to addition of apical isoproterenol.  In parallel, filters were also 
incubated without Radicicol before isoproterenol addition as a control.  DPC (CFTR Cl- 
channel inhibitor) was added to the apical side of the monolayer at the end of the 
experiment.  A 2-mV pulse was applied to the epithelia every minute throughout the 
experiment to monitor the integrity of the epithelia.  
 
Airway Fluid Clearance (AFC) Measurement 
 C57BL/6 mice are instilled with albumin (Evan’s blue tagged) in an isoosmolar 
(324 mOsm) instillate.  Alveolar instillate was administered with and without Radicicol 
[1 μM].  Temperature of mice is maintained at 37 °C using a heating pad and lamp.  After 
a 30-min period, the alveolar fluid is aspirated.  AFC, expressed as a percentage of total 
instilled volume, is calculated using the BCA protein assay (Pierce, Rockford, IL).  
Radicicol sensitivity is reported as percent reduction AFC compared to control (Ethanol) 
treated mice.  Rate of fluid removal from the alveolar airspace (alveolar fluid clearance) 
was determined by a modification the procedure described by Factor (Factor, Mutlu et al. 
2007).   
 
Two-Electrode Voltage Clamp Recordings 
Oocyte currents were acquired using standard two-electorde voltage clamp 
techniques.  I/V relationships are obtained from oocytes uninjected, water injected (46 
nanoliter (nL), or injected with wtCFTR complementary ribonucleic acid (cRNA) (5 
nanograms (ng) / 46nL).  During recording conditions, oocytes were incubated with that 
were in Ca2+ free ND96 containing 8-(4-chlorophenylthio) cAMP (cpt.cAMP) [200 uM], 
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Forskolin [10 uM], and IBMX [100 uM].  Steady current levels averaged over the last 
half of 75 ms voltage steps from -80 to +60 mV in 10 mV increments are plotted against 
voltage.  Currents were acquired using an Axon Instruments GeneClamp 500B amplifier 
and pClamp software Version 9.2 (Molecular Devices, Union City, CA) at a corner 
frequency of 500 hertz (Hz). Borosilicate glass was used to pull electrodes (Sutter 
Instruments; Novato, CA).  Pipettes were filled with 3 M potassium chloride (KCl) and 
had a resistance of 0.5-2.0 mega ohms (MOhms).  Recording solution was Ca2+-free 
oocyte recording solution (ND96) containing: 96 mM NaCl,2 KCl, 1 mM magnesium 
chloride (MgCl2), and 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES).  Membrane voltages were held at -45 millivolts (mV) and stepped to a series of 
potentials between -80 mV and +60 mV.  For construction of current-voltage (I-V) 
curves, data were averaged from the latter half of a 75-millisecond (ms) step to each 
potential.  Conductance was calculated from linear fits to the steady currents between -60 
and -40 mV.  Average conductance values were from 4-5 oocytes and reported as mean 
(+/- SEM) (McCarty, McDonough et al. 1993; Chan, Csanady et al. 2000; McCarty and 
Zhang 2001). 
 
Results 
 
Hsp90 Association with CFTR 
In a recent study published from our laboratory, it was shown that WT CFTR 
exists in cells as a high molecular weight complex as determined by a cross-linking 
method (Li, Roy et al. 2004).  Several reagents have the capability to affinity cross-link 
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CFTR in its macromolecular complex.  One of the crosslinking reagents (DSP) is cell 
permeant, an excellent crosslinker, and has a disulphide bond (S-S) that is cleaved in the 
presence of 5 % β-mercaptoethanol (β-ME).  Upon cross-linking the cells (see materials 
and methods), a band of a higher order complex greater than 250 kDa was observed as 
predicted for the CFTR macromolecular complex with its interacting partners.  
Furthermore, when cross-linked with DSP and analyzed by SDS-PAGE in the presence 
of 5 % β-ME, the 150 kDa band could be resolved yielding a large amount of protein 
appearing to be of sufficient quantity for mass spec analysis (Figure 3-1).   
  Several cross-linking reagents were tested to determine their effect on the cross-
linking of HSP-90 to CFTR.  The cells were incubated with one of three cross-linking 
reagents which are cleavable by 5% β –ME; DSP, dimethyl 3, 3´dithiobispropionimidate-
2 HCl (DTBP), and 1, 4-di-[3´-(2´-pyridyldithio)-propionamido] butane (DPDPB) (1 
mM).  The cells were lysed in RIPA buffer and immunoprecipitated with the anti-FLAG 
anti-body and probed for HSP-90.  All three detected some amount of protein, the most 
being detected by DPDPB and DSP (Figure 3-2).   
 To determine if the binding of CFTR to heat shock proteins is specific for HSP-
90, the cross-linked complex was probed for both HSP-90 and HSP-70.  The cells were  
lysed with Tris-base saline (TBS) containing 0.2% Triton-X-100 (TBS – 0.2% TX-100).  
Whereas RIPA breaks most protein-protein interactions, TBS-0.2% TX-100 does not.  
This is due to the presence of SDS and Na –deoxycholate in RIPA buffer, which disrupts 
protein-protein interactions and is useful in solubilizing integral membrane proteins. 
Using parental HEK cells as a control, it is observed that HSP-90 increases in the 
macromolecular complex upon cross-linking while HSP-70 does not (Figure 3-3). 
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Figure 3-1.  CFTR Macromolecular Complex 
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Figure 3-2.  Hsp90 Associates with CFTR 
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Figure 3-3.  Hsp-90 Specific Association with CFTR 
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Hsp90 Mass Spectrometry 
To identify interacting partners in the macromolecular complex, cross-linking 
with DSP (1mM for 10 min at 37oC) was performed, the proteins were subjected to 4-
15% SDS-PAGE, and the gel was stained with Coomassie Brilliant Blue stain.  
Approximately 2 μg of protein was loaded per lane.   A 90 kDa band was identified in the 
macromolecular complex.  The band of interest was excised, trypsin digested, and 
extracted using ZipTip C18 microcolumns.  Proteins were eluted with 50% acetonitrile, 
dried, and redissolved in 4 µL of 0.1% Trifluoroacetic acid (TFA) in water.  
Chromatography of the sample was performed using a linear gradient of increasing 
acetonitrile at a flow rate of 400 nanoliter (nL) / minute and sprayed into the mass 
spectrometer. Three types of spectra were acquired:  a full-scan of the mass spectrum, a 
zoom scan of the two most prominent ions, and MS/MS scans of the two most prominent 
ions.  Spectra were analyzed and scored using a MOWSE scoring algorithm.  Anything 
above a score of 65 is considered significant and a positive identification of the protein.  
When subjected to MALDI-TOF mass spectrometry, 27 peaks were positively identified 
as HSP-90 with a MOWSE score as high as 235 (Figure 3-4).  Thus, the 90 kDa band 
cross-linked to CFTR is shown to be Hsp90.  
 
Hsp90 Augmentation of CFTR Chloride Transport 
The Xenopus oocyte protein expression system is a well established tool for 
assessing CFTR function and proteins that regulate CFTR activity (Gurdon, Lane et al. 
1971; Bossi, Fabbrini et al. 2007) .  Two of the characteristics of CFTR currents are that 
they display a linear current-to-voltage (I/V) relationship and that can be inhibited by 
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Figure 3-4.  Mass Spectrometry: Identification of Hsp90 
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DPC (McCarty, McDonough et al. 1993).  As expected, I/V relationships were 
approximately linear and showed roughly the same reversal potential both before and 
during agonist activation (Figure 3-5). Also, diphenylamine carboxylate (DPC) [500 uM] 
reduced the conductance across the oocyte membrane by 28.3% (without DPC = 99.6 pS; 
with DPC = 28.2 pS) Negative voltages were reduced while positive voltages remained 
unaffected as previously reported (Figure 3-6) (Naren, Nelson et al. 1997; Naren, Quick 
et al. 1998).  It is expected that if Hsp90 is regulating CFTR function, this interaction 
should be detectable in the Xenopus oocyte expression system. Oocytes were injected 
with either full length HSP-90 or bovine serum albumin (BSA) (80 ng protein each) and 
recorded 30-120 minutes later (Naren, Nelson et al. 1997).  Full-length HSP-90, but not 
BSA, increased CFTR chloride conductance by 28 pS (Figure 3-7).  Injected oocytes 
displayed linear current-voltage behavior and were blocked by DPC as in Figure 3-5.  
HSP-90 and BSA did not change linear I/V behavior or reversal potential.  Conductance 
was calculated from linear fits to the steady currents between -60 and -40 mV.  As 
anticipated, Hsp90 increases CFTR chloride conductance while BSA has no effect. 
 
Radicicol Inhibits Chloride Transport 
 To extend our results and examine the effect of Hsp90 in a more physiologically 
relevant system, we used the Ussing Chamber system.  This assay allows for the  
measurement of chloride currents across a polarized epithelial monolayer grown on 
permeable supports.  In these experiments, Calu-3 cells were used to determine the effect 
of Hsp90 on CFTR chloride transport.  Calul-3 cells are human submucosal epithelial 
cells derived from lung adenocarcinoma.  They abundantly express endogenous CFTR, 
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Figure 3-5.  Expression of CFTR cRNA in Xenopus Oocytes 
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Figure 3-6.  Inhibition of CFTR in Xenopus Oocytes by DPC 
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Figure 3-7.  HSP-90 Increases CFTR Conductance in Xenopus Oocytes  
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 form tight junctions and polarized epithelial monolayers, and will exhibit CFTR 
dependent Cl- secretion in response to B2-AR receptor activation (Haws, Finkbeiner et al. 
1994; Naren, Cobb et al. 2003; Li, Dandridge et al. 2005).  It is expected that, if Hsp90 is 
having a positive effect on CFTR function, inhibiting Hsp90 with radicicol should 
decrease CFTR activity.  As expected, measurements taken in this system show an 
increase in Cl- flux in response to increasing concentrations of Isoproterenol [10 nm – 10 
uM] approaching a near maximal response . The currents could be inhibited with 500 uM 
DPC, indicative of CFTR chloride channel activity.  When the monolayers were 
pretreated for approximately 30 minutes with radicicol (RD), a specific inhibitor of 
Hsp90 with nanomolar affinity, the maximal [10 uM] isoproterenol short-circuit current 
response (~86 μA/cm2) was decreased by 29% (Figure 3-8).  
 
Radicicol Inhibition of in vivo Chloride Transport 
 To confirm our studies further establish physiological significance, the effect of 
Hsp90 inhibition was assessed on airway fluid clearance in C57BL/6 mice.  It is expected 
that if Hsp90 is inhibiting CFTR, than airway fluid clearance, a process dependent on 
CFTR (Mutlu, Adir et al. 2005) should decrease in the presence of radicicol.  Mice used 
in the airway fluid clearance assay (see materials and methods) showed a maximal airway 
fluid clearance rate under control conditions [0.1% ethanol] that was significantly 
reduced under conditions in which the mice were treated for 30 minutes with a specific 
inhibitor of Hsp90 [1 uM Radicicol] (Figure 3-9).  The temperature of the mice is 
maintained at 37 °C using a heating pad and lamp throughout the experiment.  
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Figure 3-8.  Radicicol Inhibits CFTR-Mediated Short-Circuit Currents  
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Figure 3-9.  Radicicol Inhibits in vivo Airway Fluid Transport in C57BL/6 Mice 
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Hsp90 Association Increases CFTR Phosphorylation 
To determine if the interaction between HSP-90 and CFTR is regulated by the β-
adrenergic receptor signaling pathway, the effect of Hsp90 on CFTR phosphorylation 
was determined.  CFTR is phosphorylated by PKA in response to β-agonist-mediated 
activation of the β2-AR.  The ability of a PKA-substrate antibody to detect CFTR was 
first tested (see materials and methods).  Increasing amounts of purified Flag-CFTR was 
incubated with the catalytic subunit of PKA (cPKA).  Conversely, increasing amounts of 
cPKA (0-200 units/mL) were incubated with 500 ng of purified CFTR.  Under both 
conditions, the PKA substrate antibody detected an increased amount of phosphorylated 
CFTR (Figure 3-10).     
If Hsp90 is involved in cPKA-mediated phosphorylation of the CFTR, then by 
increasing the amounts of Hsp90-CFTR complexes, this should result in increased 
phospho-CFTR in these complexes.  It was observed that by increasing the 
concentrations of DSP, a greater proportion of the total CFTR in the complex was 
phosphorylated, perhaps because of increasing Hsp90-CFTR complexes in the 
immunoprecipitations.  Furthermore, with increasing amounts of DSP, an increase in the 
amount of HSP-90 was observed in the complex (Figure 3-11).  This indicates that HSP-
90 may play a role in the PKA regulation of CFTR function.   
 
Radicicol Inhibits CFTR Phosphorylation 
To test if HSP-90 may be playing a role in PKA phosphorylation of CFTR, and 
therefore possibly CFTR function, the effect of Radicicol (RD) was determined.  With 
increasing concentrations of RD, the amount of phosphorylated CFTR decreased 
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Figure 3-10.  Phospho-PKA Substrate Antibody Recognizes CFTR 
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Figure 3-11.  Hsp90 Association Increases CFTR Phosphorylation 
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(Figure 3-12).  This suggests that HSP-90 may play a functional role in the regulation of 
CFTRs activity. 
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Figure 3-12.  Radicicol Inhibits CFTR Association with Hsp90 and CFTR 
Phosphorylation 
 
 
 
 
 59 
CHAPTER 4:  GENERAL DISCUSSION 
 
Summary of Results 
 To date most of the studies of CFTR and Hsp90 have focused on the regulation 
of CFTR trafficking from the ER to the plasma membrane.  The involvement of Hsp90 in 
regulation of channel function is poorly understood.  Earlier studies by this laboratory 
indicate that CFTR exists in a macromolecular complex with other many other regulatory 
proteins (Li and Naren 2005).  
 In this study, the hypothesis that a functionally relevant association exists 
between CFTR and Hsp90 was tested.  We found that the HEK-293 Flag-CFTR cells 
used in this study allows for a high degree of protein purification in quantities sufficient 
for mass spectroscopy.  An approximately 170 kDa band could be detected with CFTR 
specific antibodies.  This is what we expected as unlabeled CFTR is approximately 168 
kDa.  The HEK-293 Flag-CFTR cells also show increased protein expression levels 
above that observed in BHK cells transfected with wild-type (WT)-CFTR and 
CFTRHis10.  The Flag-CFTR expression was shown to be functional using a standard 
iodide efflux assay.  The HEK-293 Flag-CFTR cells responded to agonists known to 
stimulate various CFTR expressing cell lines (forskolin, IBMX, cpt.cAMP, isoproterenol, 
and adenosine).   Furthermore, these cells express sufficient quantities of protein to allow 
for mass spectrometric analysis, which has proven difficult in other cell lines.  Thus, this 
cell line is a valuable tool for the biochemical and functional characterization of CFTR 
and should prove useful for future studies assessing protein-protein interactions as they 
relate to CFTR. 
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 Using affinity cross-linking reagents (DSP & DPDPB), Hsp-90 is shown to be in 
association with CFTR in stably transfected HEK-293 cells.  Hsp90 associates with 
CFTR under these conditions more prominently than does Hsp70.  The amount of Hsp90 
in the macromolecular complex with CFTR is sufficient for mass spectrometry 
identification.  An in vitro assay for CFTR transport function (Ussing Chamber) shows 
that inhibition of Hsp90 with radicicol, an Hsp90 inhibitor with nanomolar affinity, 
decreases CFTR mediated Cl- transport.  Preliminary in vivo airway fluid clearance 
studies in mice also show that radicicol inhibits fluid transport, known to require CFTR.  
Also, Hsp90 protein increases the two-electrode voltage clamp current measured from 
Xenopus oocytes expressing CFTR chloride channels.  When assessing the 
phosphorylation status of CFTR, it is seen that under conditions that increase the 
association of Hsp90, there is also observed an increase in the phosphorylation of CFTR.  
Conversely, in the presence of increasing concentrations of radicicol, both the Hsp90 
association CFTR and the phosphorylation of CFTR tend to decrease.   
 
Discussion and Conclusion 
 One concern raised in this study is that the association we are seeing may be due 
to the fact that Flag-CFTR is over-expressed in the HEK-293 cells.  This seems not to be 
the case for several reasons.  First, if the association seen with Flag-CFTR were merely 
due to an artifact of over-expression, than one would predict that in cells that express 
normal levels of CFTR, the interaction would not exist.  However, that is not what we 
see.  In the Calu-3 cells that endogenously express CFTR, Hsp90 can be cross-linked and 
immunoprecipitated using protein A/G beads conjugated to FTR antibody.  Furthermore, 
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it is predicted that if the effect is merely due to an artifact of over-expression, than Hsp90 
inhibitors should not have an effect on CFTR function.  Yet, in Calu-3 cells grown on 
permeable supports and mounted in Ussing chambers, inhibition of Hsp90 decreases 
CFTR dependent chloride transport compare to non-treated controls.  Furthermore, in 
C57BL/6 mice which express endogenous levels of CFTR, inhibition of Hsp90 decreases 
airway fluid clearance.  Taken together, these data suggest that the association seen 
between Hsp90 and CFTR in HEK-Flag-CFTR cells is a real interaction and not merely 
an artifact of over-expression.   
 Another concern raised is whether or not the insertion of the 8 amino-acid flag 
tag is creating a non-functional CFTR protein.  This seems not to be the case for several 
reasons.  First, it has been published that the insertions of the Flag-Tag in the 4th outer 
loop of CFTR preserves the normal biophysical properties of the channel (Schultz, 
Takahashi et al. 1997).  Second, the HEK-Flag-CFTR cells respond to agonists known to 
activate CFTR such as isoproterenol and adenosine.  The very nature of theses agonists 
require that the Gs protein coupled signaling pathway be functioning in order to get a 
functional response from CFTR.  Therefore, it can be assumed that proteins such as PKA 
that are required for CFTR function are interacting with the cytosolic domains of the 
protein.  Third, we do in fact observe phosphorylation of Flag-CFTR by cPKA.  Taken 
together, these data suggest that the HEK-Flag-CFTR cells express CFTR protein that 
functions normally and can interact with cytosolic proteins as required to ensure 
regulation of channel function.   
 At present we do not know how Hsp90 is regulating CFTR through PKA.  One 
interesting interpretation of the results is that Hsp90 is interacting directly with CFTR.  
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This is certainly possible as many proteins interacting with CFTR to regulate and 
coordinate overall cellular function (Guggino and Stanton 2006).  Another interesting 
possibility is that Hsp90 may be regulating CFTR through an indirect interaction.  Hsp90 
is known act as a point of interaction with various signal transduction cascades (Citri, 
Harari et al. 2006).  Thus, it is possible that may Hsp90 may bind directly to PKA and 
regulate its interaction with the R domain of CFTR (Rich, Berger et al. 1993) (Figure     
4-1). 
Further experimentation will help elucidate the mechanism behind Hsp90 
regulation of CFTR.  It should be possible to extend our results in the Ussing chamber 
system in other cells that express CFTR such as primary cultures of alveolar Type II 
epithelial cells and 16HBE cells.  This will allow us to monitor the effect of Hsp90 
inhibitors in primary cells and another endogenously expressing cell line in addition to 
Calu-3.  Also, in these experiments we can look at the effect of knocking down Hsp90 
expression with SiRNA.  Alveolar Type II cells isolated from CF-knockout mice can be 
used as negative controls in these experiments. 
 Also, we can determine if Hsp90 can be physically cross-linked to in vitro and 
in vivo to further establish that the effect we are seeing is not due to an artifact of over-
expression.  For the in vitro experiments we can use native lung epithelial cells such as 
alveolar Type II cells and 16HBE cells.  For the in vivo experiments, we can use wild-
type and CF- mice.  We can also look at the effect of inhibitors of PKA on interaction of 
Hsp90s and CFTR. 
Furthermore, it will also be important to establish where in the cellular 
environment the interaction of Hsp90, PKA, and CFTR is taking place.  This can be done  
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Figure 4-1.   Model of CFTR Interaction with Hsp90 
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first by biotinylating the surface CFTR using a cell-impermeant biotinylating reagent.  
This will allow us to determine if the surface pool of CFTR exists in a higher molecular 
weight complex with Hsp90.  Second, we can use Fluorescence Resonance Energy 
Transfer (FRET) to determine of Hsp90, CFTR and PKA are interacting at the surface of 
the plasma membrane or if Hsp90 is regulating the endocytic recycling of CFTR.  In 
these experiments, we will also be able to look at the effect of inhibitors of PKA and 
Hsp90. 
 In summary, we have observed that Hsp90 associates with CFTR in a manor that 
suggests it is playing a functional role in the regulation of CFTR.  The present 
biochemical data indicate that this interaction is regulating CFTR though its 
phosphorylation by PKA.  The involvement of Hsp90 in the regulation of CFTR may 
provide a physiological mechanism for adapting to the metabolic state of the cell, as both 
CFTR and Hsp90 are dependent upon ATP for their function.  It is shown here that 
inhibitors of Hsp90 can reduce airway fluid clearance.  Theses results warrant further 
investigation into the role of CFTR and Hsp90 in diseases of impaired airway fluid 
clearance such as edema.  Such results could even be of benefit to cancer patients 
undergoing treatment with Hsp90 inhibitors that experience symptoms (such as grade 3 
pancreatitis, shortness of breath, and gastrointestional side effects) that could be 
explained by a decrease in CFTR function.   
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